ArticleNature communications2026
Iterative and data-driven ortholog mining enables reliable discovery of stereoselective ketoreductases.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ketoreductases (KREDs) enable stereoselective alcohol synthesis and are widely used industrially. Yet identifying process-compatible and selective enzymes for non-native substrates remains challenging, requiring extensive screening. Here, we present an iterative ortholog mining strategy to explore functional space. Starting from a known KRED, we sample its orthogroup across 48 evolutionarily distant variants, identifying five enzymes producing pharmaceutically relevant alcohols (de/ee 42.8% to >99%). Refined sampling of 60 phylogenetically close orthologs yields further improved ketoreductases (de/ee 98% to >99%). Because ortholog mining is genome-dependent, it overlooks enzymes from unsequenced organisms. To address this, we use our dataset to explore homologous KREDs beyond the sampled orthogroup, expanding the search space fifteenfold. To this end, we develop the automated pipeline HomoLogic, whose functional descriptors, fed into interpretable models, predict KRED performance accurately (R² up to 0.76). Overall, we show that evolutionarily balanced ortholog panels combined with data-driven modeling enable efficient discovery of stereoselective biocatalysts.
Indexed as
Identifiers
42881161What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.